Results 221 to 230 of about 14,023 (271)

Toward a Unified Framework in Molecular Neurobiology of Alzheimer's Disease: Revisiting the Pathophysiological Hypotheses. [PDF]

Mol Neurobiol
Hein ZM, Karikalan B, Gopalakrishna PK, Dhevi K, Alkatiri A, Hussan F, Mohd Moklas MA, Jagadeesan S, Che Ramli MD, Che Mohd Nassir CMN, Vishnumukkala T.   +10 more
europepmc   +1 more source

Modulation of BDNF/TrkB Signalling Pathway in Alzheimer's Disease: Mechanistic Insights and the Role of Stem Cell Therapy. [PDF]

Biomedicines
Harun ZZ, Abdul Azhar A, Kim YJ, Ibrahim FW, Ng MH, Tan JK, Lokanathan Y.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Successive cleavage of β-amyloid precursor protein by γ-secretase

Seminars in Cell & Developmental Biology, 2020
γ-Secretase is a multimeric aspartyl protease that cleaves the membrane-spanning region of the β-carboxyl terminal fragment (βCTF) generated from β-amyloid precursor protein. γ-Secretase defines the generated molecular species of amyloid β-protein (Aβ), a critical molecule in the pathogenesis of Alzheimer's disease (AD).
Satoru, Funamoto, Shinji, Tagami, Masayasu, Okochi, Maho, Morishima-Kawashima   +3 more
openaire   +2 more sources

ADAMs family members as amyloid precursor protein α‐secretases

Journal of Neuroscience Research, 2003
AbstractIn the non‐amyloidogenic pathway, the Alzheimer's amyloid precursor protein (APP) is cleaved within the amyloid‐β domain by α‐secretase precluding deposition of intact amyloid‐β peptide. The large ectodomain released from the cell surface by the action of α‐secretase has several neuroprotective properties.
Allinson, Tobias M. J., Parkin, Edward T., Turner, Anthony J., Hooper, Nigel M.   +3 more
openaire   +2 more sources

Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein

Journal of Neurochemistry, 1995
Abstract: The amyloid precursor protein (APP) is a membrane‐spanning glycoprotein that is the source of βA4 peptides, which aggregate in Alzheimer's disease to form senile plaques. APP is cleaved within the βA4 sequence to release a soluble N‐terminal derivative (APPsol), which has a wide range of trophic and protective functions.
S, Bodovitz, M T, Falduto, D E, Frail, W L, Klein   +3 more
openaire   +2 more sources

β-Secretase Processing of the Alzheimer's Amyloid Protein Precursor (APP)

Journal of Molecular Neuroscience, 2003
An integral membrane aspartyl protease, BACE, is responsible for beta-secretase processing of the beta-amyloid precursor protein (APP) to the large secreted sAPPbeta and membrane-bound CTFbeta of 99 residues. CTFbeta is subsequently cleaved within the membrane by gamma-secretase to the amyloid beta protein (Abeta) that is deposited in the Alzheimer's ...
Laura, Marlow, Melissa, Cain, Miguel A, Pappolla, Kumar, Sambamurti   +3 more
openaire   +2 more sources

Recognition of the amyloid precursor protein by human γ-secretase

Science, 2019
The machinery behind amyloid peptides β-Amyloid peptides, which are derived from amyloid precursor protein (APP), form the plaques in the brain that are characteristic of Alzheimer's disease. Zhou et al.
Rui Zhou, Guanghui Yang, Xuefei Guo, Qiang Zhou, Jianlin Lei, Yigong Shi   +5 more
openaire   +2 more sources

Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers

Trends in Molecular Medicine, 2014
Recently revised diagnostic guidelines for Alzheimer's disease (AD) emphasise the use of biomarkers, heralding a paradigm shift towards a more biological definition of the disorder. Currently available biomarkers offer added diagnostic accuracy in certain situations, but their performance in terms of early diagnostic sensitivity and specificity does ...
Robert, Perneczky, Panagiotis, Alexopoulos, Alexander, Kurz   +2 more
openaire   +2 more sources

Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond

Drug News & Perspectives, 2010
This review evaluates past and present clinical trials, as well as the current preclinical drug candidates focused on treating Alzheimer's disease (AD), in order to better assess the trends in AD drug discovery in context with specific drug mechanisms.
openaire   +2 more sources